Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Safety, Tolerability, and Efficacy Study of VX-264 in Participants With Type 1 Diabetes
Sponsor: Vertex Pharmaceuticals Incorporated
Summary
The purpose of the study is to evaluate the safety, tolerability, and efficacy of VX-264 in participants with type 1 diabetes (T1D).
Official title: A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of VX-264 in Subjects With Type 1 Diabetes Mellitus
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
7
Start Date
2023-05-16
Completion Date
2026-05-29
Last Updated
2025-08-11
Healthy Volunteers
No
Conditions
Interventions
VX-264
Allogeneic human stem cell-derived islets.
Locations (16)
UHealth Diabetes Research Institute
Miami, Florida, United States
University of Chicago
Chicago, Illinois, United States
Massachusetts General Hospital
Boston, Massachusetts, United States
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania, United States
University of Pittsburgh Medical Center Montefiore
Pittsburgh, Pennsylvania, United States
University of Wisconsin
Madison, Wisconsin, United States
University of Alberta, Edmonton
Edmonton, Canada
Montreal Clinical Research Institute
Montreal, Canada
Toronto General Hospital (TGH)
Toronto, Canada
Vancouver General Hospital
Vancouver, Canada
Dresden Center for Islet Transplantation
Dresden, Germany
IRCCS Ospedale San Raffaele
Milan, Italy
Leiden University
Leiden, Netherlands
Hopiteaux Universitaires de Geneve
Geneva, Switzerland
Churchill Hospital
Headington, United Kingdom
Royal Victoria Infirmary
Newcastle upon Tyne, United Kingdom